<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p52" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_52{left:36px;bottom:25px;letter-spacing:0.07px;word-spacing:0.01px;}
#t2_52{left:341px;bottom:30px;}
#t3_52{left:348px;bottom:25px;letter-spacing:0.11px;}
#t4_52{left:377px;bottom:30px;}
#t5_52{left:381px;bottom:25px;letter-spacing:0.07px;word-spacing:-0.1px;}
#t6_52{left:540px;bottom:30px;}
#t7_52{left:546px;bottom:25px;letter-spacing:0.07px;}
#t8_52{left:44px;bottom:77px;letter-spacing:0.1px;word-spacing:-0.05px;}
#t9_52{left:44px;bottom:63px;letter-spacing:0.1px;}
#ta_52{left:285px;bottom:860px;letter-spacing:-0.32px;word-spacing:0.06px;}
#tb_52{left:285px;bottom:827px;letter-spacing:-0.24px;}
#tc_52{left:996px;bottom:873px;letter-spacing:-0.1px;}
#td_52{left:1043px;bottom:853px;letter-spacing:-0.22px;word-spacing:0.13px;}
#te_52{left:1093px;bottom:833px;letter-spacing:-0.09px;}
#tf_52{left:1098px;bottom:28px;letter-spacing:0.32px;}
#tg_52{left:415px;bottom:778px;letter-spacing:0.34px;word-spacing:-0.16px;}
#th_52{left:36px;bottom:487px;letter-spacing:-0.1px;}
#ti_52{left:415px;bottom:700px;letter-spacing:-0.1px;}
#tj_52{left:415px;bottom:682px;letter-spacing:-0.1px;}
#tk_52{left:415px;bottom:664px;letter-spacing:-0.1px;}
#tl_52{left:415px;bottom:572px;letter-spacing:-0.09px;}
#tm_52{left:415px;bottom:554px;letter-spacing:-0.1px;}
#tn_52{left:415px;bottom:425px;letter-spacing:-0.11px;}
#to_52{left:415px;bottom:324px;letter-spacing:-0.1px;}
#tp_52{left:415px;bottom:306px;letter-spacing:-0.06px;}
#tq_52{left:415px;bottom:288px;letter-spacing:-0.09px;word-spacing:-0.05px;}
#tr_52{left:415px;bottom:269px;letter-spacing:-0.06px;}
#ts_52{left:415px;bottom:251px;letter-spacing:-0.1px;}
#tt_52{left:786px;bottom:681px;letter-spacing:-0.13px;word-spacing:0.03px;}
#tu_52{left:786px;bottom:564px;letter-spacing:-0.13px;word-spacing:0.04px;}
#tv_52{left:1039px;bottom:564px;letter-spacing:-0.11px;}
#tw_52{left:786px;bottom:428px;letter-spacing:-0.13px;word-spacing:0.04px;}
#tx_52{left:1039px;bottom:428px;letter-spacing:-0.11px;}
#ty_52{left:786px;bottom:286px;letter-spacing:-0.15px;word-spacing:0.05px;}
#tz_52{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_52{font-size:9px;font-family:ArialMT_5tg;color:#000;}
.s1_52{font-size:5px;font-family:ArialMT_5tg;color:#000;}
.s2_52{font-size:12px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_52{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_52{font-size:17px;font-family:ArialMT_5tg;color:#0065A4;}
.s5_52{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s6_52{font-size:17px;font-family:Arial-BoldMT_jz;color:#000;}
.s7_52{font-size:17px;font-family:Arial-BoldMT_5te;color:#0065A4;}
.s8_52{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts52" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-BoldMT_jz;
	src: url("fonts/Arial-BoldMT_jz.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

</style>
<div id="pg52Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg52" style="-webkit-user-select: none;"><object width="1210" height="935" data="52/52.svg" type="image/svg+xml" id="pdf52" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_52" class="t s0_52">Version 4.2024, 5/1/2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_52" class="t s1_52">® </span>
<span id="t3_52" class="t s0_52">(NCCN </span>
<span id="t4_52" class="t s1_52">® </span>
<span id="t5_52" class="t s0_52">), All rights reserved. NCCN Guidelines </span>
<span id="t6_52" class="t s1_52">® </span>
<span id="t7_52" class="t s0_52">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_52" class="t s2_52">Note: All recommendations are category 2A unless otherwise indicated. </span>
<span id="t9_52" class="t s2_52">Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged. </span>
<span id="ta_52" class="t s3_52">NCCN Guidelines Version 4.2024 </span>
<span id="tb_52" class="t s3_52">Cancer of the Supraglottic Larynx </span>
<span id="tc_52" class="t s4_52">NCCN Guidelines Index </span>
<span id="td_52" class="t s4_52">Table of Contents </span>
<span id="te_52" class="t s4_52">Discussion </span>
<span id="tf_52" class="t s5_52">SUPRA-4 </span>
<span id="tg_52" class="t s5_52">CLINICAL STAGING </span>
<span id="th_52" class="t s5_52">Node-positive disease </span>
<span id="ti_52" class="t s5_52">Amenable to larynx-preserving </span>
<span id="tj_52" class="t s5_52">(conservation) surgery </span>
<span id="tk_52" class="t s5_52">(T1–2,N+ and selected T3,N1) </span>
<span id="tl_52" class="t s6_52">Requiring (amenable to) total </span>
<span id="tm_52" class="t s5_52">laryngectomy (Most T3,N1–3) </span>
<span id="tn_52" class="t s5_52">T4a,N1–N3 </span>
<span id="to_52" class="t s5_52">T4b,N1–3 </span>
<span id="tp_52" class="t s5_52">or </span>
<span id="tq_52" class="t s5_52">Unresectable nodal disease </span>
<span id="tr_52" class="t s5_52">or </span>
<span id="ts_52" class="t s6_52" data-mappings='[[2,"fi"]]'>Unﬁt for surgery </span>
<span id="tt_52" class="t s7_52">Treatment of Primary and Neck (SUPRA-5) </span>
<span id="tu_52" class="t s5_52">Treatment of Primary and Neck </span><span id="tv_52" class="t s7_52">(SUPRA-6) </span>
<span id="tw_52" class="t s5_52">Treatment of Primary and Neck </span><span id="tx_52" class="t s7_52">(SUPRA-8) </span>
<span id="ty_52" class="t s7_52">Treatment of Head and Neck Cancer (ADV-1) </span>
<span id="tz_52" class="t s8_52">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
